首页> 外文期刊>中华医学杂志(英文版) >Effect of Inhaled Budesonide on Interleukin-4 and Interleukin-6 in Exhaled Breath Condensate of Asthmatic Patients
【24h】

Effect of Inhaled Budesonide on Interleukin-4 and Interleukin-6 in Exhaled Breath Condensate of Asthmatic Patients

机译:吸入布地奈德对哮喘患者呼出气冷凝液中白细胞介素4和白细胞介素6的影响

获取原文
获取原文并翻译 | 示例
       

摘要

Background:Studies ofinterleukin (IL)-4 and IL-6 in the exhaled breath condensate (EBC) of asthmatic patients are limited.This study was to determine the effect of inhaled corticosteroid (ICS) treatment on IL-4 and IL-6 in the EBC of asthmatic patients.Methods:In a prospective,open-label study,budesonide 200 μg twice daily by dry powder inhaler was administered to 23 adult patients with uncontrolled asthma (mean age 42.7 years) for 12 weeks.Changes in asthma scores,lung function parameters (forced expiratory volume in 1 s [FEV1],peak expiratory flow [PEF],forced expiratory flow at 50% of forced vital capacity [FEF50],forced expiratory flow at 75% of forced vital capacity,maximum mid-expiratory flow rate) and the concentrations of IL-4 and IL-6 in EBC were measured.Results:Both asthma scores and lung function parameters were significantly improved by ICS treatment.The mean IL-4 concentration in the EBC was decreased gradually,from 1.92 ± 0.56 pmol/L before treatment to 1.60 ± 0.36 pmol/L after 8 weeks of treatment (P < 0.05) and 1.54 ± 0.81 pmol/L after 12 weeks of treatment (P < 0.01).However,the IL-6 concentration was not significantly decreased.The change in the IL-4 concentration was correlated with improvements in mean FEV1,PEF and FEF50 values (correlation coefficients-0.468,-0.478,and-0.426,respectively).Conclusions:The concentration of IL-4 in the EBC of asthmatic patients decreased gradually with ICS treatment.Measurement of IL-4 in EBC could be useful to monitor airway inflammation in asthmatics.
机译:背景:哮喘患者呼出气冷凝液(EBC)中白介素(IL)-4和IL-6的研究非常有限。本研究旨在确定吸入糖皮质激素(ICS)治疗对哮喘患者IL-4和IL-6的影响方法:在一项前瞻性,开放标签研究中,对23例未控制哮喘(平均年龄42.7岁)的成年患者(每日平均42.7岁)给予200克每日一次布地奈德干粉吸入器治疗,持续12周。肺功能参数(1秒内的呼气量[FEV1],峰值呼气量[PEF],50%的强制肺活量时的强制呼气流量[FEF50],75%的肺活量时的强制呼气流量,最大呼气中期结果:ICS治疗可显着改善哮喘评分和肺功能参数; EBC中平均IL-4浓度从1.92开始逐渐降低。治疗前±0.56 pmol / L至1.60±0.36 pmol / L治疗8周后为L(P <0.05),治疗12周后为1.54±0.81 pmol / L(P <0.01)。但是,IL-6的浓度并没有显着降低。与平均FEV1,PEF和FEF50值的改善相关(分别为-0.468,-0.478和-0.426)。结论:ICS治疗使哮喘患者EBC中IL-4的浓度逐渐降低。 EBC中的-4可能有助于监测哮喘患者的气道炎症。

著录项

  • 来源
    《中华医学杂志(英文版)》 |2016年第7期|819-823|共5页
  • 作者单位

    Department of Respiratory and Critical Care Medicine, Peking University First Hospital, Beijing 100034, China;

    Department of Respiratory and Critical Care Medicine, Peking University First Hospital, Beijing 100034, China;

    Department of Respiratory and Critical Care Medicine, Peking University First Hospital, Beijing 100034, China;

    Department of Medical Statistics, Peking University First Hospital, Beijing 100034, China;

    Department of Respiratory and Critical Care Medicine, Peking University First Hospital, Beijing 100034, China;

  • 收录信息 中国科学引文数据库(CSCD);中国科技论文与引文数据库(CSTPCD);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号